An Open Label 2-arm Study to Evaluate the Impact of Adjuvant Bevacizumab on Invasive Disease Free Survival in Triple Negative Breast Cancer


Phase 3
18 Years
N/A
Open (Enrolling)
Both
Breast Cancer

Thank you

Trial Information

An Open Label 2-arm Study to Evaluate the Impact of Adjuvant Bevacizumab on Invasive Disease Free Survival in Triple Negative Breast Cancer


Inclusion Criteria:



- adult patients, >=18 years of age;

- operable primary invasive breast cancer;

- completed definitive loco-regional surgery;

- primary tumor centrally confirmed as triple negative.

Exclusion Criteria:

- locally advanced breast cancers;

- previous breast cancer history;

- clinically significant cardiovascular disease.

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Invasive disease-free survival

Outcome Time Frame:

Event driven

Safety Issue:

No

Principal Investigator

Clinical Trials

Investigator Role:

Study Director

Investigator Affiliation:

Hoffmann-La Roche

Authority:

France: AFSSAPS

Study ID:

BO20289

NCT ID:

NCT00528567

Start Date:

December 2007

Completion Date:

January 2015

Related Keywords:

  • Breast Cancer
  • Breast Neoplasms

Name

Location
Hinsdale, Illinois  60521
New Britain, Connecticut  06052
Bettendorf, Iowa  52722
Albany, Georgia  31701
Birmingham, Alabama  35294
Fountain Valley, California  92708
Miami, Florida  33176
Columbia, Missouri  65203
Albany, New York  12208
Cleveland, Ohio  44195
Nashville, Tennessee  37203-1632
Austin, Texas  78705
Flint, Michigan  48532
McLean, Virginia  22101
Little Rock, Arkansas  72205-7199
Hackensack, New Jersey  07601
Baltimore, Maryland  21287
Charlotte, North Carolina  
South Burlington, Vermont  
Charleston, South Carolina  
Washington, District of Columbia